Author Correction: DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Affiliations

• ¹ Novartis Institutes for BioMedical Research, Basel, Switzerland. [email protected].
• ² Novartis Institutes for BioMedical Research, Basel, Switzerland.
• ³ Ridgeline Discovery, Basel, Switzerland.
• ⁴ Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
• ⁵ Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
• ⁶ Swiss Institute for Experimental Cancer Research (ISREC), École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
• ⁷ Novartis Institutes for BioMedical Research, Cambridge, MA, USA. [email protected].
• ⁸ Ridgeline Discovery, Basel, Switzerland. [email protected].